Hormonal therapy of prostatic cancer: current status
- Authors: Veliev EI1, Okhrits VE1, Veliev EI1, Okhrits VE1
-
Affiliations:
- Issue: No 4 (2011)
- Pages: 64-68
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279195
- ID: 279195
Cite item
Full Text
Abstract
References
- Oefelein M. G., Feng A., Scolieri M. J. et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56:1021-1024.
- Schulman С. С., Irani J., Morote J. et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur. Urol. Suppl. 2010; 9: 675-691.
- Morote J., Planas J., Orsola A. et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J. Urol. (Baltimore) 2007; 178: 1290-1295.
- Tombal B., Berges R. Optimal control of testosterone: a clinical case-based approach of modem androgen deprivation therapy. Eur. Urol. Suppl. 2008; 7: 15-21.
- Tombal В., Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard? Eur. Urol. Suppl. 2005; 4: 30-36.
- Berges R. Eligard 6: achieving optimal testosterone control with the convenience of a twice-a-year formulation. Eur. Urol. Suppl. 2007; 6: 840-845.
- European Association of Urology guidelines on prostate cancer. 2010.
- Wilt T., Nair B., MacDonald R., Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst. Rev. 2009; CD003506.
- Loblaw D. A., Virgo K. S., Nam R. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 2007; 25:1596-1605 .
- Medical Research Council Prostate Cancer Working Party Investigators group. Immediate versus deffered treatment for advanced prostatic cancer: initial results of the medical research Council Trial. Br. J. Urol. 1997; 79: 235-246.
- Messing E. M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7: 472-479.
- Schroder F. H., Kurth K. H., Fossa S. D. Early versus delayed endocrine treatment of T2-T3 pN1-3М0 prostate cancer without local treatment of the primary tumour: final results of European local treatment of cancer protocol 30846 after 13 years of follow-up (a randomized controlled trial). Eur. Urol. 2009; 55: 14-22.
- Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002; 360: 103-106.
- Pilepich M. V., Winter K., Lawton C. A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61: 1285-1290.
- McLeod D. G., Iversen P., See W. A. et al. Bicalutamide 150 mg plus standard care alone for early prostate cancer. Br. J. Urol. Int. 2006; 97: 247-254.
- Siddiqui S. A., Boorjian S. A., Inman B. et al. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J. Urol. (Baltimore) 2008; 179: 1830-1837.
- Calais da Silva, Bono A. V., Whelan P. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Urooncological Group. Eur. Urol. 2009; 55: 1269- 1277.
- Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. Br. J. Urol. Int. 2007; 99 (Suppl. 1): 19-22.
- Calais da Silva, Concalves F., Santos A. et al. Evaluation of quality of life, side effects and duration of therapy in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation. Eur. Urol. Suppl. 2008; 7: 205, abstr. 540.
- Montorsi F., Berges R., Irani J., Schulman C. Hormone therapy for prostate cancer: exploring current controversies. Eur. Urol. Suppl. 2009; 8: